Pathology Home Diagnostic Tests Consultations faculty index Fellowships index Research index Residency index
Rita Braziel, MD
Medical Director, Hematopathology
Rank: Professor
Clinical Services: Hematopathology
Clinical Interests: All areas of diagnostic hematopathology Standardization of molecular diagnostic testing in hematopathology
Research Interests: Identification of biologic markers of diagnostic , prognostic and therapeutic importance in malignant lymphomas
 
Education:
1972    University of New Mexico, Biology and Chemistry- B.S.
1977    University of New Mexico - MD
Boards:
Anatomic and Clinical Pathology
Previous Position:
1981-84    National Cancer Institute NIH, Co-director of Immunology and Immunopathology/Flow Cytometry Laboratory
Selected References:
  • Fan G, Kotylo P, Neiman RS, and Braziel RM: Comparison of fascin expression in anaplastic large cell lymphoma and classical Hodgkin’s disease. Am J Clin Pathol 119:199-204, 2003.
  • Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, and Rosenbaum JT: Expression of B- cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101:815-821, 2003.
  • O’Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, and Braziel RM: SPOTLIGHT: Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 17:481-487, 2003.
  • Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, and Fisher RI: A phase 2 trial of CHOP chemotherapy followed by tositumomab/Iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102;1606-1612, 2003.
  • Braziel RM. Molecular diagnosis of hematopoeitic disorders. Hematology 2003. American Society of Hematology, pages 278-284, 2003.
  • Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, and Staudt LM for the Leukemia and Lymphoma Molecular Profiling Project. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198;851-862, 2003.
  • Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Lynch JC, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, and Chan WC: Confirmation of the molecular subclassification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103;275-282, 2004.
  • Rimsza L, Roberts RZ, Unger J, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs D, Spier C, Fisher RI, Staudt LM, Miller T, and Grogan T. Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival irrespective of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103;4251-4258, 2004.
  • Kussick SJ, Kalnoski M, Braziel RM, and Wood BL. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Amer J Clin Pathol 121;464-472, 2004.

Last Updated: 02/17/2010